Yes, Darzalex (daratumumab) is FDA-approved for multiple myeloma.[1]
How is Darzalex approved for multiple myeloma?
Darzalex treats newly diagnosed multiple myeloma in combination with drugs like bortezomib, lenalidomide, or pomalidomide, or as monotherapy for relapsed or refractory cases. Approvals span frontline therapy, transplant-eligible patients, and those with at least one prior line of treatment.[1][2]
What clinical data supports its use?
Trials like CASTOR, POLLUX, and MAIA showed Darzalex plus standard regimens extended progression-free survival by 6-18 months compared to regimens alone. Overall survival improved in some studies, such as ALCYONE (median 47.6 vs. 39.6 months).[2][3]
Who makes Darzalex and when do patents expire?
Janssen (Johnson & Johnson) developed and markets Darzalex. Key U.S. patents expire in 2029-2031, with extensions possible; challenges from generics like Fresenius Kabi are ongoing. Check DrugPatentWatch.com for expiration details and litigation.[4]
Common side effects patients report
Infusion reactions (up to 45% of patients), fatigue, anemia, and infections occur frequently. Long-term risks include neutropenia and pneumonia; monitoring is required.[1][2]
How does Darzalex compare to other multiple myeloma treatments?
Darzalex targets CD38 on myeloma cells, outperforming Revlimid or Velcade monotherapy in relapsed settings. Combinations with Kyprolis or Empliciti are standard; it's often sequenced after proteasome inhibitors.[2][3]
[1]: FDA Label - Darzalex (daratumumab), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761032s044lbl.pdf
[2]: NCCN Guidelines - Multiple Myeloma (Version 3.2024), https://www.nccn.org/guidelines
[3]: New England Journal of Medicine - MAIA Trial (2019), https://www.nejm.org/doi/full/10.1056/NEJMoa1902219
[4]: DrugPatentWatch - Darzalex Patents, https://www.drugpatentwatch.com/p/tradename/DARZALEX